Key Points
- BioNTech CEO Ugur Sahin sold 30,000 shares at an average price of $96.22, generating $2.89 million. The pre-arranged Rule 10b5-1 transaction reduced his direct ownership by 5.78% to 489,209 shares.
- Sahin has made numerous additional BioNTech sales since early September, indicating a sustained pattern of insider selling rather than a one-time transaction.
- BioNTech recently missed quarterly earnings and revenue estimates, while analysts maintain a “Moderate Buy” consensus with an average price target of $126 versus the stock’s roughly $96 price.
BioNTech SE Sponsored ADR (NASDAQ:BNTX - Get Free Report) CEO Ugur Sahin sold 30,000 shares of the firm's stock in a transaction that occurred on Friday, September 18th. The stock was sold at an average price of $96.22, for a total transaction of $2,886,600.00. Following the completion of the transaction, the chief executive officer directly owned 489,209 shares of the company's stock, valued at approximately $47,071,689.98. This trade represents a 5.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Ugur Sahin also recently made the following trade(s):
- On Thursday, September 17th, Ugur Sahin sold 34,000 shares of BioNTech stock. The shares were sold at an average price of $98.60, for a total transaction of $3,352,400.00.
- On Wednesday, September 16th, Ugur Sahin sold 15,000 shares of BioNTech stock. The shares were sold at an average price of $96.09, for a total transaction of $1,441,350.00.
- On Tuesday, September 15th, Ugur Sahin sold 34,000 shares of BioNTech stock. The stock was sold at an average price of $96.49, for a total value of $3,280,660.00.
- On Monday, September 14th, Ugur Sahin sold 41,000 shares of BioNTech stock. The stock was sold at an average price of $99.45, for a total value of $4,077,450.00.
- On Friday, September 11th, Ugur Sahin sold 45,000 shares of BioNTech stock. The shares were sold at an average price of $96.93, for a total value of $4,361,850.00.
- On Thursday, September 10th, Ugur Sahin sold 20,500 shares of BioNTech stock. The shares were sold at an average price of $96.31, for a total value of $1,974,355.00.
- On Wednesday, September 9th, Ugur Sahin sold 36,000 shares of BioNTech stock. The shares were sold at an average price of $97.78, for a total value of $3,520,080.00.
- On Tuesday, September 8th, Ugur Sahin sold 37,000 shares of BioNTech stock. The stock was sold at an average price of $99.20, for a total value of $3,670,400.00.
- On Friday, September 4th, Ugur Sahin sold 31,500 shares of BioNTech stock. The stock was sold at an average price of $103.52, for a total value of $3,260,880.00.
- On Thursday, September 3rd, Ugur Sahin sold 45,000 shares of BioNTech stock. The stock was sold at an average price of $102.85, for a total value of $4,628,250.00.
BioNTech Stock Down 2.6%
BNTX stock opened at $96.06 on Friday. The stock has a 50-day simple moving average of $97.38 and a two-hundred day simple moving average of $94.93. BioNTech SE Sponsored ADR has a twelve month low of $79.52 and a twelve month high of $124.00. The firm has a market capitalization of $24.29 billion, a PE ratio of -12.27 and a beta of 1.29. The company has a quick ratio of 7.80, a current ratio of 7.85 and a debt-to-equity ratio of 0.01.
BioNTech (NASDAQ:BNTX - Get Free Report) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($2.53) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.40) by ($0.13). BioNTech had a negative return on equity of 6.86% and a negative net margin of 63.54%.The firm had revenue of $122.31 million during the quarter, compared to analysts' expectations of $180.18 million. During the same period in the previous year, the company posted ($1.60) earnings per share. The company's quarterly revenue was down 59.5% compared to the same quarter last year. On average, equities analysts predict that BioNTech SE Sponsored ADR will post -6.37 EPS for the current fiscal year.
Hedge Funds Weigh In On BioNTech
A number of institutional investors have recently made changes to their positions in the stock. Flossbach Von Storch SE purchased a new stake in shares of BioNTech in the 2nd quarter valued at $207,142,000. BNP Paribas Financial Markets raised its position in BioNTech by 43.0% in the 4th quarter. BNP Paribas Financial Markets now owns 1,578,094 shares of the company's stock worth $150,235,000 after purchasing an additional 474,796 shares during the period. First Trust Advisors LP lifted its stake in BioNTech by 116.0% in the first quarter. First Trust Advisors LP now owns 839,991 shares of the company's stock worth $74,658,000 after purchasing an additional 451,124 shares during the last quarter. Assenagon Asset Management S.A. bought a new stake in BioNTech in the second quarter worth $39,385,000. Finally, SEB Asset Management AB purchased a new stake in BioNTech during the first quarter valued at about $17,804,000. Institutional investors own 15.52% of the company's stock.
Analyst Upgrades and Downgrades
Several research analysts have commented on the stock. Sanford C. Bernstein reissued a "market perform" rating on shares of BioNTech in a report on Friday, June 5th. UBS Group reaffirmed a "buy" rating on shares of BioNTech in a report on Wednesday. Wall Street Zen downgraded BioNTech from a "hold" rating to a "sell" rating in a research report on Saturday, August 8th. Berenberg Bank set a $140.00 price objective on BioNTech in a research note on Wednesday. Finally, Morgan Stanley decreased their target price on BioNTech from $126.00 to $119.00 and set an "overweight" rating on the stock in a research note on Wednesday, July 8th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $126.00.
Check Out Our Latest Stock Report on BNTX
About BioNTech
(
Get Free Report)
BioNTech SE is a biotechnology company focused on developing immunotherapies and vaccines for cancer and other serious diseases. Its research platforms include messenger RNA, cell therapies, protein-based therapeutics, antibody therapies and small-molecule immunomodulators.
The company is best known for Comirnaty, its COVID-19 vaccine developed and commercialized globally in collaboration with Pfizer. BioNTech is also advancing a broad oncology pipeline that includes individualized and off-the-shelf cancer vaccines, antibody-based treatments, cell therapies and combination approaches designed to stimulate or direct the immune system against tumors.
BioNTech was founded in 2008 and is headquartered in Mainz, Germany.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
